

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 5,618,913  
(45) ISSUED : April 8, 1997  
(75) INVENTOR : Jens Brange, et al.  
(73) PATENT OWNER : Novo Nordisk A/S  
(95) PRODUCT : NOVOLOG® (insulin aspart (rDNA origin))


This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,618,913 based upon the regulatory review of the product NOVOLOG® (insulin aspart (rDNA origin)) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 61 days

from April 8, 2014, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 26th day of March 2008.

  
\_\_\_\_\_  
Jon W. Dudas  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office